The p38 MAP kinase inhibitor dilmapimod ameliorates airway inflammation induced by ozone challenge in healthy volunteers

Trial Profile

The p38 MAP kinase inhibitor dilmapimod ameliorates airway inflammation induced by ozone challenge in healthy volunteers

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2012

At a glance

  • Drugs Dilmapimod (Primary) ; Prednisolone
  • Indications Asthma; Chronic obstructive pulmonary disease; Inflammation
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Sep 2012 New trial record
    • 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top